Spravato® (esketamine): A Fast-Acting Breakthrough for Treatment-Resistant Depression
When traditional antidepressants aren't enough, Spravato® offers a new path forward. Discover the first FDA-approved nasal spray designed specifically for adults who have struggled to find relief.
%20Large.jpeg)
Why Spravato?
Experience Relief Beyond Traditional Medicine
At Neurobehavioral Medicine Consultants, we understand that living with Major Depressive Disorder (MDD) is an uphill battle—especially when medications haven't worked. Spravato® (esketamine) is a prescription nasal spray that, when taken with an oral antidepressant, can begin reducing depressive symptoms in as little as 24 hours for some patients.
Expert Supervision: Our clinical team provides a safe, comfortable environment for your treatment sessions.
Rapid Results: Unlike traditional pills that can take weeks to work, Spravato targets different neural pathways for faster relief.
Insurance Guidance: We help navigate coverage options, as Spravato is covered by many major insurance plans and Medicare.
How Spravato Works
Spravato works differently than standard SSRIs or SNRIs. While most antidepressants target neurotransmitters like serotonin or norepinephrine, Spravato targets the glutamate system.During a TMS session, you’ll sit comfortably in a chair (you can listen to music or watch TV if you like). A small curved device with an electromagnetic coil is positioned against your head, targeting the prefrontal cortex – the area implicated in mood disorders. The device generates quick magnetic pulses (similar in type and strength to those used in an MRI machine) that induce tiny electrical currents in the brain.
Glutamate Targeting
It acts on NMDA receptors to increase the release of glutamate, the brain’s most abundant chemical messenger.
Synaptic Connectivity
This process helps restore synaptic connections in brain regions associated with mood and emotional regulation.
FAQs
Explore common questions about Transcranial Magnetic Stimulation and its benefits for mental health.
TRD is generally defined as Major Depressive Disorder that has not responded adequately to at least two different antidepressant treatments of adequate dose and duration.
Spravato is esketamine, a more potent component of the ketamine molecule. It is FDA-cleared specifically for depression and is administered via nasal spray, whereas "IV ketamine" is typically an off-label treatment delivered through an intravenous line.
The most common side effects include dissociation (feeling "spaced out"), dizziness, nausea, sedation, and a temporary increase in blood pressure. These usually resolve within the two-hour observation period.
No. Because of the sedative effects, you must have a pre-arranged ride home. You should not drive or operate heavy machinery until the day after your treatment.
Yes, most major commercial insurance providers and Medicare cover Spravato for patients who meet the clinical criteria for Treatment-Resistant Depression. Our team will assist you with the prior authorization process.
Have questions or ready to get started?
Share your information and a member of our team will reach out with next steps.
Please don’t include personal medical details in this form. We’ll discuss your care privately with our team.
